HSBC Holdings
MRSN

HSBC Holdings’s Mersana Therapeutics MRSN Stock Holding History

HSBC Holdings’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,220
Closed -$8.78K – 2988
2025
Q2 		$8.78K Buy
1,220
+720
+144% +$6.33K ﹤0.01% 2997
2025
Q1 		$4.38K Sell
500
-32
-6% -$494 ﹤0.01% 3003
2024
Q4 		$18.3K Sell
532
-27
-5% -$1.4K ﹤0.01% 3054
2024
Q3 		$25.7K Buy
559
+58
+12% +$2.56K ﹤0.01% 2930
2024
Q2 		$24.9K Sell
501
-3
-0.6% -$217 ﹤0.01% 2864
2024
Q1 		$56.5K Buy
+504
New +$50.1K ﹤0.01% 2927
2022
Q3 		– Sell
-749
Closed -$85K – 3141
2022
Q2 		$85K Buy
+749
New +$70.4K ﹤0.01% 3064

Other funds holding MRSN

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
AV
Alamea Verwaltungs Edison, New Jersey $125M AUM 27.56% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HSBC Holdings's MRSN Position: Q3 2025 in Review

HSBC Holdings sold out of Mersana Therapeutics (MRSN) in Q3 2025, closing a stake of 1,220 shares — an estimated $8.78K sold.

HSBC Holdings first reported a position in MRSN in Q2 2022 and held it in 7 quarters. The position peaked at $85K in Q2 2022. 49 funds tracked by Wall St. Rank hold MRSN as of Q3 2025.

  • HSBC Holdings reported no remaining Mersana Therapeutics position as of Q3 2025 after selling out during the quarter.
  • HSBC Holdings sold 1,220 Mersana Therapeutics shares in Q3 2025, an estimated $8.78K.
  • HSBC Holdings first reported a position in Mersana Therapeutics in Q2 2022 and held it in 7 quarters.
  • HSBC Holdings's Mersana Therapeutics position peaked at $85K in Q2 2022.
  • 49 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q3 2025.

Based on HSBC Holdings's 13F filing for Q3 2025, filed 13 Nov 2025.